

From biomedical research to drug discovery

The **SCHOOL OF PHARMACEUTICAL SCIENCES AT TSINGHUA UNIVERSITY** is dedicated to improving human health through excellent education, innovative research and accelerated translation.

Tsinghua University's School of Pharmaceutical Sciences (SPS) was established to educate new generations of pharmaceutical researchers and professionals, and to conduct innovative research to address the world's significant health issues. Leveraging Tsinghua's strengths in related disciplines such as chemistry, chemical engineering, material science, medical engineering and information technology, SPS is committed to advancing understanding of unsolved diseases and translating research discoveries and technological developments

into novel medicines and therapeutic approaches.

A focus on cutting-edge biomedical research

SPS is at the forefront of pharmaceutical sciences, investigating various therapeutic approaches, including small molecules, biologics, gene therapy, cell therapy and medical devices. It seeks to drive drug discovery through major advances in emerging fundamental biology with translational potential, enabling pharmaceutical technologies, and disease understanding and targeting, all

highly interdisciplinary areas.

The Institute for Stem Cell Biology and Regenerative Medicine (ISCBRM) is a fine example of SPS endeavors. Its work spans fundamental, translational and clinical research in regenerative medicine, including stem cell biology in normal and diseased tissues, tissue development and regeneration, and cell/tissue engineering.

Advanced translational platforms

Translational medicine is at the core of SPS' development plan. Supported by Tsinghua University and in partnership with notable organizations and corporations, SPS has established several key platforms to expedite the process of drug discovery from bench to bedside. These include core platforms, as well as early-stage incubators and funds. SPS seeks to cooperate with partners to create an integrated ecosystem for global pharmaceutical innovation and, ultimately, impact human health.

A recent example is the Global Health Drug Discovery

Institute (GHDDI), jointly founded by Tsinghua University, the Bill & Melinda Gates Foundation and the Beijing Municipal Government. It aims to address some of the most pressing disease challenges faced by developing countries via developing a transformative platform with exceptional biomedical R&D capabilities.

A place for talented and aspiring scientists

SPS has world-class faculty engaging in innovative pharmaceutical research. Moving forward, it plans to significantly expand its faculty and has been actively seeking outstanding researchers from academia and industry who share the SPS passion and ambition to tackle diseases. Together, we will create vital knowledge and enabling technologies, pushing translational science into new medicine and treatments. ■



86-10-62793117
 tpsps_hr@tsinghua.edu.cn
 www.sps.tsinghua.edu.cn

